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Abstract
Background: The success of HPV vaccination programs will require awareness regarding HPV associated diseases
and the benefits of HPV vaccination for the general population. The aim of this study was to assess the level of
awareness and knowledge of human papillomavirus (HPV) infection, cervical cancer prevention, vaccines, and
factors associated with HPV awareness among young women after birth of the first child.
Methods: This analysis is part of a cross-sectional study carried out at Hospital Maternidade Leonor Mendes de
Barros, a large public maternity hospital in Sao Paulo. Primiparous women (15-24 years) who gave birth in that
maternity hospital were included. A questionnaire that included questions concerning knowledge of HPV, cervical
cancer, and vaccines was applied. To estimate the association of HPV awareness with selected factors, prevalence
ratios (PR) were estimated using a generalized linear model (GLM).
Results: Three hundred and one primiparous women were included; 37% of them reported that they “had ever
heard about HPV”, but only 19% and 7%, respectively, knew that HPV is a sexually transmitted infection (STI) and
that it can cause cervical cancer. Seventy-four percent of interviewees mentioned the preventive character of
vaccines and all participants affirmed that they would accept HPV vaccination after delivery. In the multivariate
analysis, only increasing age (P for trend = 0.021) and previous STI (P < 0.001) were factors independently
associated with HPV awareness ("had ever heard about HPV”).
Conclusions: This survey indicated that knowledge about the association between HPV and cervical cancer among
primiparous young women is low. Therefore, these young low-income primiparous women could benefit greatly
from educational interventions to encourage primary and secondary cervical cancer prevention programs.
Background
Genital infection by oncogenic human papillomavirus
(HPV) is a necessary factor in the development of cancer
of the cervix [1]. Although the HPV family of viruses
includes more than 100 different viral genotypes, HPV 16
and 18 were identified in about 70% of cervical cancer
cases [2], while HPV 6 and 11 can cause genital warts [3].
Two prophylactic vaccines to prevent infections by
high risk HPV viral genotypes 16 and 18 were available;
ideally they should be administered before sexual debut
or shortly thereafter to achieve optimal vaccine effective-
ness. The US Advisory Committee on Immunization
Practices (ACIP) recommended routine HPV vaccina-
tion of girls at age 9-12 years and catch-up vaccination
for females aged 13-26 years who have not been pre-
viously vaccinated or who have not completed the full
immunization series [4].
However, providing a vaccine “against cancer” to ado-
lescent girls raises several challenges because many
young unmarried girls and women face significant chal-
lenges in accessing the health care necessary to meet
their sexual and reproductive health needs [5]. For this
reason, in some countries school vaccination programs
have been established as a strategy to vaccinate girls
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lower socio-economic status are more likely to drop out
of school, therefore, opportunities for catch-up vaccina-
tion are valuable to improve coverage among the at risk
young female population.
Then, the success of HPV vaccination programs will
require improving awareness regarding HPV, cervical
cancer, and the benefits of HPV vaccination for the gen-
eral population.
Probably, knowledge about HPV has been changing in
recent years, given public awareness campaigns around
the announcement of the regulatory approval and public
announcements of the HPV vaccines.
Thereafter, identifying which groups of women remain
unfamiliar with these subjects and would, therefore,
benefit from educational messages is crucial, particularly
in the target age group for HPV vaccination.
Hence, the aim of this study was to assess the level of
awareness and knowledge of HPV infection, cervical
cancer prevention, and vaccines, and factors associated
with HPV awareness among low-income young women
after first delivery in the city of São Paulo, Brazil. The
rationale for studying this population is that first deliv-
ery health care services could represent a suitable
opportunity to offer HPV vaccines for adolescents and
young women who have not been previously vaccinated.
Methods
Study population
This study is part of a cross-sectional study carried out
from June 2006 to February 2007. The study was con-
ducted out at Hospital Maternidade Leonor Mendes de
Barros (HMLMB), one of the largest public maternity
hospitals in the city of Sao Paulo, Brazil. All primiparous
women aged between 15 and 24 years who had been liv-
ing in the metropolitan area of Sao Paulo for at least six
months and gave birth at this hospital after more than
32 weeks of gestation were eligible for the study. The
following exclusion criteria, as previously published [6],
were applied: non Brazilian, inability or refuse to give
informed consent or immunodeficiency (including
AIDS/HIV infection checked in medical records).
The study protocol was submitted and approved by the
National Ethical Committee (CONEP) (number 188/2006).
Women were recruited to take part in the study dur-
ing the post-delivery follow-up period in the hospital.
Eligible women were contacted by a health professional
(a nurse or physician) and asked whether they wanted
to know about a study on prevention of cancer of the
cervix; those interested had a post-natal visit scheduled
within 43 to 60 days after delivery to be enrolled in the
study. Women had to attend the post-natal visit and
sign the informed consent form to be included in the
study.
A total of 509 women were invited to participate: 24
refused, 163 women previously interested in participat-
ing did not return to the post-natal visit, and 322
attended the post-natal visit. However, 18 women were
not eligible (11 attended the post-natal visit more than
60 days after delivery, one had HIV positive serology,
one had more than one delivery, and five were over
24 years old). Three eligible women were excluded by
the investigators: one had an acute infectious disease
and two aged <18 years lived in a reformatory and had
difficulty obtaining a legal representative’ss i g n a t u r eo n
the informed consent form within the study period.
Therefore, 301 primiparous women were included in the
analysis.
Data collection
During the routine post-natal visit, women were enrolled
and interviewed, in an appropriate setting ensuring priv-
acy, by trained interviewers. Using a standardized ques-
tionnaire (Additional file 1), information obtained
included demographic characteristics, sexual behaviour,
reproductive history, contraceptive practice, smoking
habits, and awareness and knowledge of HPV, cervical
cancer (causes and prevention), vaccines, and HPV vac-
cine acceptability. Only women who answered questions
about awareness of each one of these subjects affirma-
tively were asked the following open questions, respec-
tively: Could you explain how HPV may be caught and
what it may cause? Could you explain what the causes(s)
of cervical cancer are? Could you explain how the exami-
nation to prevent cervical cancer or “cytological tests”
examination is performed? Could you explain what vac-
cines are? Do you know what vaccines you have been
given?
Answers to open questions were grouped in categories
according their similarities to be quantified.
Statistical analysis
Levels of awareness and knowledge of HPV, cervical can-
cer, and vaccines were expressed as percentages.
To estimate the association of HPV awareness with
selected factors, prevalence ratios (PR) and 95% confi-
dence intervals (CI) were calculated, with HPV awareness
as the dependent variable and various factors as indepen-
dent variables. Most independent variables were grouped
into two or more categories. For ordered categorical
independent variables, tests for linear trend (Chi-square
for trend) in the PR were conducted by categorizing the
independent variables and entering the continuous
scores. Variables selected in univariate analysis at a 0.20
significance level were included in the multivariate analy-
sis. PR and their 95% CI were estimated using a general-
ized linear model (GLM) with binomial distribution and
log link function [7]. Statistical significance was assessed
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less than 0.05 was considered to indicate statistical signif-
icance. All analyses were performed using STATA
version 8.2 [9].
Results
The mean age of study participants was 19.9 years
(median 20.0 years). Over 60% were white and most
women (88%) had at least eight years of schooling (the
first grade). About two thirds reported incomes (includ-
ing earnings of all family members) of less than four
minimum wages per month (equivalent to US$ 479.20
during the study period).
Awareness of HPV among these young women after
first delivery was low: only one third of them reported
that they had ever heard of HPV. Among those who
had heard of it, less than a quarter knew that HPV can
cause cervical cancer; about half knew that HPV is a
sexually transmitted infection (STI), and only two parti-
cipants knew that it can cause genital warts. Only 7%
(n = 20) of all participants answered both that HPV is
an STI and that it can cause cervical cancer.
When asked about cervical cancer cause(s), very few
participants admitted knowing the cause(s) of cervical
cancer (8%) and only 6% of women in the sample enum-
erated HPV as a cervical cancer cause.
Slightly more than a half of the total number of parti-
cipants referred to knowing about the examination to
prevent cervical cancer or cytological tests. However,
only 27% answered that in this test some kind of mate-
rial is collected (a sample of cells from the cervix, cells,
secretion, fluid, etc.).
Seventy-four percent of interviewees mentioned the
preventive character of vaccines, and only 57% of them
answered correctly concerning vaccines that had been
given to them (giving the name of at least one vaccine
or the name of the disease that the vaccine targeted).
All participants affirmed that they would accept vacci-
nation after delivery if the HPV vaccine were available
(Table 1).
HPV awareness increased with increasing age (P for
trend = 0.003) and with increasing years of schooling
(P for trend = 0.039) (Table 2). Table 3 shows the distri-
bution of HPV awareness according to sexual behaviour,
reproductive characteristics, and contraception history.
Only ever having had a previous STI was significantly
associated with HPV awareness (PR = 2.55; 95% CI:
1.93-3.36).
All selected variables (age, years of schooling, marital
status, income and previous STI), were included in the
multivariate analysis model. However, when years of
schooling and income were included, the model did not
converge. Then, the variable income was taken out. In
the analysis including the other four variables, years of
schooling (P for trend = 0.307) and marital status (P =
0.296) were not significantly associated with HPV
awareness. The multivariate analysis revealed that only
age (P for trend = 0.021) and previous STI (P < 0.001)
were independently associated with HPV awareness.
The prevalence ratio of HPV awareness for women aged
19-21 years was 1.32 with a 95% CI of 0.87-2.01, and for
women aged 22-24 years it was 1.63 with a 95% CI of
1.07-2.48 (reference group: women 15-18 years old).
Women who reported a previous STI were more likely
to be aware of HPV (PR = 2.05; 95% CI: 1.46-2.87) com-
pared to women who had never had any STI.
Discussion
The awareness of HPV among these young primiparous
women was low, as only one third of the participants
reported having “ever heard about HPV”, despite the
fact that the present analysis began 16 days after public
news and announcements about the first regulatory
approval of one of the HPV vaccines, on June 08, 2006
[10], and the fact that participants in the present study
had relatively high levels of education within the Brazi-
lian context.
Surveys conducted previously and before the regula-
tory approval of HPV vaccines also showed a low level
of awareness of HPV (30-40%) [11-14]. The results of
t h ep r e s e n ts t u d ya r ei nl i n ew ith other recent studies,
carried out after regulatory approval of HPV vaccina-
tion, that showed limited levels of awareness of HPV. In
the United Kingdom and Italy (where HPV vaccine is
free of charge for girls of 12 years of age), only about
24% and 30% of respondents, respectively, reported
awareness of HPV [15,16].
In the present study, awareness of HPV was the first
question and we did not ask any open questions con-
cerning knowledge of HPV, cervical cancer causes and
prevention, or vaccines when the participant was not
aware of any of theses subjects, in order to avoid influ-
encing the answers to the open questions or obtaining
an answer given correctly by luck, as can occur in stu-
dies that use multiple-choice answers.
Only 19% and 7% of the present study participants,
respectively, knew that HPV is an STI and that it can
cause cervical cancer. Another study, carried out in
north-eastern Brazil, assessing young women (16-
23 years) showed similar results to the present study: less
than 10% of participants acknowledged that HPV might
lead to cervical cancer; however, a higher proportion of
those women (67%) knew that HPV is sexually trans-
mitted [17]. This difference might be explained by the
fact that these women had higher educational levels than
women in the present study (61% and 50% respectively
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because the authors [17] used five multiple-choice
answers per question, a bias cannot be excluded.
We also studied the relationship between HPV aware-
ness and several factors. The multivariate analysis high-
lights two factors: having had a previous STI and
increasing age remained as factors associated with HPV
awareness. Accordingly, some authors reported that
increasing age (women 14-24 years) [16] and having had
a personal, familiar, or friendly history of previous STI
or cervical cancer were associated with an increased
awareness of HPV and accurate knowledge of the HPV-
cervical cancer link [13,14,16].
Half of all participants reported awareness concerning
cervical cancer prevention by cytological test, although a
smaller number were aware of how it is performed. The
query was intended to estimate how many women were
aware, and whether they were able to recognize the dif-
ferences between the ordinal gynecological test and the
cytological tests. Based on our data, just 27% of the
young primiparous women were able to recognize the
differences.
Other studies regarding cytological tests estimated
whether the women were aware of their purpose, and
hence are not suitable for direct comparisons. They
reported a variety of results (10-89%) concerning the
interviewees’ awareness of the cytological tests’ purposes
[11,16,17].
In the present study, the awareness regarding vaccines
was high, with 74% of the interviewees mentioning their
preventative aspect, and 57% of women could identify at
least one of the vaccines they had received; that is, they
could name the vaccine or the disease which it was
intended to prevent.
Table 1 Answers about awareness and knowledge of HPV, cervical cancer (causes and prevention), and vaccines
among 301 participants
Total %
Had ever heard about HPV 110 37,0
Knowledge about how HPV may be caught and what it may
cause
62 20,6
When asked to explain how HPV may be caught and and what
it may cause
1
HPV is a sexually transmitted disease 58 19,0
HPV can cause cervical cancer 22 7,3
HPV can cause genital warts 2 0,7
Did not know 2 0,7
Knowledge about cervical cancer causes 23 7,6
When asked to explain what they knew about cervical cancer
causes
1
HPV 19 6,3
Hereditary disease 1 0,3
Sexual transmitted disease 1 0,3
Did not know 2 0,7
Knowledge about the examination to prevent cervical cancer
or “Pap smear”
157 52,2
When asked to explain what “Pap smear” is Collection of material, secretion, cells, etc. 80 26,6
Like a gynecological examination
2 41 13,6
Repeated the phrase “examination to prevent cervical cancer’’ 22 7,3
Other 11 3,7
Did not know 3 1,0
Knowledge about vaccines 246 81,7
When asked to explain what they knew about Prevention of disease 223 74,1
Treatment 13 4,3
Other 7 2,3
Did not know 3 1,0
Knowledge about how many vaccines received 183 60,8
When asked to explain which vaccines received Answered at least one vaccine correctly 171 56,8
Other 7 2,3
Did not know 5 1,7
Acceptance of vaccination against HPV after delivery
3 301 100,0
1 Participants could give more than one answer.
2 Participant seems to know something about it but it is doubtful that she could distinguish it from another gynecological examination.
3 The interviewer first explained what vaccines are and about HPV vaccine.
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the inadequate knowledge of HPV and cervical cancer,
all participants reported that they would accept vaccina-
tion after delivery if the HPV vaccine was available. As
other studies have reported, there was a generally
favourable attitude toward HPV vaccines; despite the
low level of knowledge about the link between HPV and
cervical cancer, 91% and 88% of women would agree to
receive the vaccine in surveys that found that only 15%
[18] and 38% [19], respectively, had heard of HPV.
However, it is important to report that the question
about the knowledge of vaccines preceded the question
about the acceptability of the HPV vaccine, and for the
participants who did not know the answer to the first
question, one brief explanation on the prevention of
illnesses through vaccines and on the HPV prophylactic
vaccine was given by the interviewers in the present study.
In fact, the main factor associated with the acceptance
of the HPV prophylactic vaccine in studies carried out
prior to its approval was the knowledge of the partici-
pants concerning the purpose of vaccines [20,21].
Public acceptance and usage of a prophylactic vaccine
are related to the level of knowledge about the disease,
which the vaccine will provide protection from [22].
Education about HPV prophylactic vaccines, cervical
cancer, and related topics is needed in every country
where the vaccine is available.
The main limitation of this study is that 32% of eligi-
ble women who were previously interested in participat-
ing did not return to the post-natal visit. The likely
Table 2 Prevalence ratios and corresponding 95% confidence intervals (CI) for HPV awareness according to selected
socio-demographic characteristics and smoking habits among 301 young primiparous women, Sao Paulo, Brazil,
2006-2007
Total HPV awareness Prevalence ratio 95% CI P
Age (years) 0.003*
15-18 90 26.7% 1
19-21 119 35.3% 1.32 [0.87-2.02]
22-24 92 47.8% 1.79 [1.20-2.69]
Ethnic group 0.923
White 190 37.9% 1
Black 31 32.3% 0.85 [0.50-1.46]
Mulatto 77 35.1% 0.93 [0.65-1.32 ]
Indian 3 33.3% 0.88 [1.76-4.40 ]
Years of schooling 0.039*
≤7 37 29.7% 1
8 67 28.4% 0.95 [0.51-1.78]
9o r1 0 64 35.9% 1.21 [0.67-2.19]
≥11 133 42.9% 1.44 [0.85-2.46]
Marital status 0.093
Living with partner 245 38.8% 1
Single 56 26.8% 0.69 [0.44-1.10]
Income
1 0.054*
<1 13 38.5% 1
1-3 188 31.9% 0.83 [0.40-1.70]
4-6 80 45.0% 1.17 [0.56-2.43]
7-10 11 27.3% 0.71 [0.22-2.31]
>1 0 5 80.0% 2.08 [0.92-4.70]
Smoking habits 0.493
Never 231 35.5% 1
Ever
2 70 40.0% 1.13 [0.81-1.58]
1 In number of minimum wages per month (one minimum wage = R$250.00 or US$119.80; US$1.00 = R$ 2.09, February 2007). Data missing for 4 participants.
2 Included current and former smokers.
*Chi-square for trend.
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attending the post-natal visit at our hospital is the avail-
ability of post-natal services in public health care centres
near their homes, and therefore women may have pre-
ferred those for convenience. However, we compared
participants and non-respondents using medical hospital
records and they did not differ according to several fac-
tors: age (P = 0.205), marital status (P = 0.480), smoking
habits (P = 0.183), prenatal health care (P = 0.436), and
number of prenatal health care visits (P = 0.214). There-
fore, this limitation is unlikely to have affected our
results significantly.
In Brazil, Quadrivalent and Bivalent HPV vaccines
have been approved by regulatory authorities for females
aged, respectively, 9 to 26 years and 10 to 25 years but
they are not yet included in public vaccination programs
[23,24]. Despite the implementation of a national cervi-
cal cancer screening program based on cytology in
Brazil, about 20,000 cervical cancer cases occur each
year [25], indicating a need for revised efforts in educa-
tion, prevention, and detection.
Although the possibility of knowledge of HPV can be
changing in Brazil, probably it has not been changing
significantly, because no large educational campaign
about HPV for the population has been improved by the
government in the last years.
Our findings could add information to knowledge of the
Latin American scenario reflecting the views of young
women of lower socio-economic status after first delivery.
Despite the possibility to provide a large number of infor-
mation to mothers during the prenatal and postpartum
periods, this group of women had low levels of knowledge
of HPV and cervical cancer development and prevention.
Thus, these women could benefit greatly from educational
interventions to encourage participation in primary and
secondary cervical cancer prevention programs.
Conclusions
Young women of low socio-economic status after first
delivery had low levels of knowledge of HPV and cervi-
cal cancer development and prevention. Thus, opportu-
nities for educational interventions during the prenatal
and postpartum periods are valuable to improve knowl-
edge about these subjects.
Additional material
Additional file 1: QUESTIONNAIRE. Structured epidemiologic
questionnaire with information about demographic characteristics, sexual
behavior, reproductive history, contraceptive practice, smoking habits
and questions concerning knowledge of HPV, cervical cancer, and
vaccines.
Table 3 Prevalence ratios and corresponding 95% confidence intervals (CI) for HPV awareness according to selected
sexual behaviours, reproductive characteristics, and history of contraception among 301 young primiparous women,
Sao Paulo, Brazil, 2006-2007
Total HPV awareness Prevalence ratio 95% CI P
Age at first sexual intercourse 0.307
≤15 132 33.3% 1
>1 5 169 39.1% 1.17 [0.86-1.59]
Number of lifetime sexual partners 0.238*
1 120 37.5% 1
2-3 116 28.5% 0.76 [0.52-1.10]
≥4 65 49.2% 1.31 [0.94-1.84]
Previous STI
1 0.002
No 292 34.9% 1
Yes 9 88.9% 2.55 [1.93-3.36]
Abortion 0.603
No 282 36.2% 1
Yes 19 42.1% 1.16 [0.67-2.02]
Contraception 0.398
No 74 32.4% 1
Yes 227 37.9% 1.17 [0.81-1.69]
1STI: Sexually Transmitted Infection.
*Chi-square for trend.
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